What question did this study set out to answer?

This commentary evaluates the effectiveness of volrustomig in dual PD-1/CTLA-4 inhibition and its potential impact on treatment outcomes.

May 15, 2026

Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig

Key Points

This commentary evaluates the effectiveness of volrustomig in dual PD-1/CTLA-4 inhibition and its potential impact on treatment outcomes.
Discussion of dual PD-1/CTLA-4 inhibition
Analysis of the bispecific antibody format
Consideration of dose-dependent adverse events
Volrustomig shows durable responses in several cancers.
Dose-dependent immune-related adverse events were reported.
Evaluation of the therapeutic index suggests potential improvements over existing treatments.

Abstract

Dual PD-1/CTLA-4 inhibition improves outcomes in several cancers but remains limited by toxicity. A recent article reports the first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody, demonstrating durable responses, but dose-dependent immune-related adverse events were also observed. This commentary examines whether the bispecific format meaningfully improves the therapeutic index and considers priorities for the next phase of development.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Clinical Cancer Research

Institutions

Massachusetts General Hospital

Mass General Brigham

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.